Dr Ciesielski speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago about SurVaxM, an investigational vaccine against glioblastoma.
He outlines results from 63 patients treated with standard therapy — surgery followed by chemoradiation and then adjuvant chemotherapy, then the vaccine, in which 91% of patients receiving SurVaxM were still living 12 months after initiating treatment, compared to 61% in a historical analysis of patients treated with standard therapy alone.
Dr Ciesielski also highlights that 96% achieved six-month progression-free survival, compared to 54% among the historical comparison group, and looks forward to further trial expansion.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.